









市場行情
/
股票
/
nasdaq-lenz
/

LENZ Therapeutics Inc

LENZ

16.890USD

-0.730-4.14%

收盤 12/23, 16:00（美東）報價延遲15分鐘

482.86M總市值

虧損本益比TTM



LENZ Therapeutics Inc

16.890

-0.730-4.14%

概覽公司財務分析

概覽

公司

財務

分析

關於 LENZ Therapeutics Inc 公司

LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.

LENZ Therapeutics Inc簡介



公司代碼LENZ

公司名稱LENZ Therapeutics Inc

上市日期Jun 25, 2021

CEOSchimmelpennink (Evert)

員工數量42

證券類型Ordinary Share

年結日Jun 25

公司地址- -

城市- -

上市交易所NASDAQ OMX - NASDAQ BASIC

國家- -

郵編- -

電話- -

網址- -

公司代碼LENZ

上市日期Jun 25, 2021

CEOSchimmelpennink (Evert)

LENZ Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. James Mccollum

Independent Director

631.10K

+1.69%

Mr. Marc Odrich

Chief Medical Officer

99.60K

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

5.39K

+68.95%

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

Dr. Zachary (Zach) Scheiner, Ph.D.

Independent Director

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

Ms. Shelley B. Thunen

Independent Director

Dr. Frederic (Fred) Guerard, Pharm.D.

Independent Director

Jeff W. George

Independent Chairman of the Board

Mr. Evert (Eef) Schimmelpennink

President, Chief Executive Officer, Secretary, Director

名稱

名稱/職務

職務

持股

持股變動

Mr. James Mccollum

Independent Director

631.10K

+1.69%

Mr. Marc Odrich

Chief Medical Officer

99.60K

Dr. Daniel R. (Dan) Chevallard

Chief Financial Officer

5.39K

+68.95%

Mr. Shawn Olsson

Chief Commercial Officer

4.73K

Dr. Zachary (Zach) Scheiner, Ph.D.

Independent Director

Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA

Independent Director

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

RA Capital Management, LP

13.36%

Alpha Wave Global, LP

11.54%

Versant Ventures

8.49%

Ridgeback Capital Management, L.P.

6.24%

The Vanguard Group, Inc.

4.24%

其他

56.13%

持股股東

佔比

RA Capital Management, LP

13.36%

Alpha Wave Global, LP

11.54%

Versant Ventures

8.49%

Ridgeback Capital Management, L.P.

6.24%

The Vanguard Group, Inc.

4.24%

其他

56.13%

股東類型

持股股東

佔比

Venture Capital

34.49%

Investment Advisor

26.63%

Hedge Fund

23.81%

Investment Advisor/Hedge Fund

15.67%

Individual Investor

2.52%

Research Firm

2.01%

Pension Fund

0.17%

Bank and Trust

0.13%

Insurance Company

0.02%

機構持股



更新時間: 10月5日週日

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

267

30.95M

100.67%

+981.38K

2025Q2

245

29.52M

104.44%

-639.13K

2025Q1

245

28.95M

104.22%

-285.84K

2024Q4

225

27.65M

100.55%

-350.42K

2024Q3

204

26.43M

96.17%

-1.73M

2024Q2

197

25.06M

103.06%

+4.18M

2024Q1

204

22.41M

93.92%

+12.70M

2023Q4

200

7.73M

92.24%

-2.14M

2023Q3

200

7.54M

90.13%

-2.49M

2023Q2

212

7.64M

91.96%

-2.29M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

RA Capital Management, LP

4.18M

14.65%

Jun 30, 2025

Alpha Wave Global, LP

3.61M

12.66%

Jun 30, 2025

Versant Ventures

2.88M

10.1%

-135.30K

-4.48%

Sep 18, 2025

Ridgeback Capital Management, L.P.

1.95M

6.84%

Apr 14, 2025

The Vanguard Group, Inc.

1.29M

4.52%

+91.53K

+7.65%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

1.27M

4.44%

+216.45K

+20.60%

Jun 30, 2025

UBS Financial Services, Inc.

881.48K

3.09%

+214.32K

+32.12%

Jun 30, 2025

Paradigm BioCapital Advisors LP

1.72M

6.02%

+297.23K

+20.93%

Jun 30, 2025

72 Investment Holdings, LLC

1.02M

3.57%

Jun 30, 2025

Tang Capital Management, LLC

897.62K

3.15%

+130.68K

+17.04%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

State Street SPDR S&P Pharmaceuticals ETF

1.18%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.04%

Virtus LifeSci Biotech Clinical Trials ETF

0.68%

Invesco Dorsey Wright Healthcare Momentum ETF

0.44%

Invesco Dorsey Wright SmallCap Momentum ETF

0.27%

iShares U.S. Pharmaceuticals ETF

0.22%

ProShares Ultra Nasdaq Biotechnology

0.11%

iShares Micro-Cap ETF

0.09%

Invesco Nasdaq Biotechnology ETF

0.08%

iShares Biotechnology ETF

0.06%

State Street SPDR S&P Pharmaceuticals ETF

佔比1.18%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

佔比1.04%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.68%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比0.44%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0.27%

iShares U.S. Pharmaceuticals ETF

佔比0.22%

ProShares Ultra Nasdaq Biotechnology

佔比0.11%

iShares Micro-Cap ETF

佔比0.09%

Invesco Nasdaq Biotechnology ETF

佔比0.08%

iShares Biotechnology ETF

佔比0.06%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

公告日期

類型

比率

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

Mar 19, 2024

Merger

7→1

常見問題

LENZ Therapeutics Inc的前五大股東是誰？



LENZ Therapeutics Inc的前五大股東如下：
RA Capital Management, LP
持有股份：4.18M
佔總股份比例：14.65%。
Alpha Wave Global, LP
持有股份：3.61M
佔總股份比例：12.66%。
Versant Ventures
持有股份：2.88M
佔總股份比例：10.10%。
Ridgeback Capital Management, L.P.
持有股份：1.95M
佔總股份比例：6.84%。
The Vanguard Group, Inc.
持有股份：1.29M
佔總股份比例：4.52%。